PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.

about

Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date

P2860

Q58785964-F2BE720F-D7FE-4202-AEF5-1C328FCCE0EF

P2860

PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.

Item

http://www.wikidata.org/entity/Q41994564

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

PI3Kδ-selective and PI3Kα/δ-co ...... r B-cell non-Hodgkin lymphoma.

@en

type

Item

label

PI3Kδ-selective and PI3Kα/δ-co ...... r B-cell non-Hodgkin lymphoma.

@en

prefLabel

PI3Kδ-selective and PI3Kα/δ-co ...... r B-cell non-Hodgkin lymphoma.

@en

P1476

PI3Kδ-selective and PI3Kα/δ-co ...... r B-cell non-Hodgkin lymphoma.

@en

P2093

Benjamin L Lampson

http://www.w3.org/2001/XMLSchema#string

Jennifer R Brown

http://www.w3.org/2001/XMLSchema#string

P2860

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

The PTEN tumor suppressor gene and its role in lymphoma pathogenesis

Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

Discovery and in vivo evaluation of (S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and related PI3Kδ inhibitors for inflammation and autoimmune disease

First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.

The role of PI3K in immune cells

A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation

Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

P304

1267-1279

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/13543784.2017.1384815

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28945111

http://www.w3.org/2001/XMLSchema#string

P932

5747968

http://www.w3.org/2001/XMLSchema#string

PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.

about

P2860

P2860

PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932